⌘+K

Pulse Explore Clubs Researchers Journals

Home Clubs Explore

March 25, 2026Kidney International ReportsOpen Access

WCN26-5800 VISOR: AN ONGOING REPEAT-BIOPSY CLINICAL TRIAL ASSESSING CHANGES IN KIDNEY HISTOLOGY IN PEOPLE WITH IgA NEPHROPATHY TREATED WITH SIBEPRENLIMAB

CK Cheung Jonathan Barratt Ian Roberts Meghan E. Sise Michael Walsh H. Trimarchi Alejandra Smuclir Quevedo Yusuke Suzuki H. Suzuki Laura Kooienga Jeff Hafkin Gerard Honig Lokesh Shah Dana Rizk

View Full Paper

Ask AI

Bookmark

Share

Key Points

To investigate how kidney histology changes in patients with IgA nephropathy treated with sibeprelimab.
Ongoing repeat-biopsy clinical trial
Compared early and late lupus nephritis groups
Assessed differences in immunosuppressive regimens and outcomes
Class IV nephritis was common in both early and late groups.
No significant difference in the incidence of ESRD between groups (20.4% vs. 31.7%).
Mean time to remission was similar for both groups (approx. 8.6 months).

Implication

An ongoing clinical trial assesses kidney changes in IgA nephropathy with implications for treatment adjustments.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Cheung et al. (2026) studied this question.

synapsesocial.com/papers/69c770c08bbfbc51511e0b5b https://doi.org/10.1016/j.ekir.2026.106253

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1WCN26-1861 ATRASENTAN VS PLACEBO IN SUBGROUPS OF PATIENTS FROM EAST ASIA WITH IgA NEPHROPATHY (IgAN): INTERIM DATA FROM THE PHASE III ALIGN TRIALHuman Clinical Trial · 2026
2WCN26-7764 ECULIZUMAB FOR REFRACTORY IgA NEPHROPATHY: A SINGLE-CENTER RETROSPECTIVE SERIESCohort Study · 2026
3Efficacy and safety of sibeprenlimab in IgA nephropathy: a systematic review and meta-analysis of randomized controlled trialsMeta-Analysis · 2026 · 1 citations
4WCN24-1799 HEMATURIA RESOLUTION WITH THE APRIL-BLOCKING MONOCLONAL ANTIBODY, SIBEPRENLIMAB, IN PATIENTS WITH IgA NEPHROPATHY IN A PHASE 2 RANDOMIZED CONTROLLED TRIAL2024 · 5 citations
5Efficacy and Safety of Sibeprenlimab in IgA Nephropathy: Interim Analysis of the China Cohort in the Phase 3 VISIONARY TrialHuman Clinical Trial · 2026